ALLO

Allogene Therapeutics, Inc.

1.97 USD

Last updated Sep 4, 20:17 UTC

Yesterday HIGH

$2.01

Yesterday LOW

$1.92

52w HIGH

$4.46

52w LOW

$1.04

EPS

-0.13

PE

-15.12

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Allogene Therapeutics, Inc. stock is up 0.77% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 7 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

19 Aug 17:38	19 Feb, 2027	2.50	CALL	910	2112

Advanced Data Unlock

Benzinga Newsdesk

Wed Apr 15, 2026

Allogene Therapeutics Announces The Publication Of Pre-Clinical Data For ALLO-329, An Investigational Allogeneic CAR T Product Developed Specifically For Autoimmune Diseases, In The Journal 'Nature Communications'

Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical ModelsDual
Benzinga Newsdesk

Wed Apr 15, 2026

Reported Earlier, Allogene Therapeutics Prices 87.5M Common Shares At $2.00 Per Share In $175M Public Offering
Benzinga Insights

Tue Apr 14, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Newsdesk

Tue Apr 14, 2026

Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Perform and raises the price target from $1.6 to $3.85.
Benzinga Newsdesk

Tue Apr 14, 2026

Argus Research Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

Argus Research analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Perform and raises the price target from $1.6 to $3.85.
Benzinga Newsdesk

Tue Apr 14, 2026

Citizens Maintains Market Outperform on Allogene Therapeutics, Raises Price Target to $8

Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and raises the price target from $5 to $8.
Avi Kapoor

Tue Apr 14, 2026

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.
Avi Kapoor

Tue Apr 14, 2026

Apple To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, including upgrades/downgrades, see analyst ratings page.
Benzinga Newsdesk

Tue Apr 14, 2026

Baird Maintains Outperform on Allogene Therapeutics, Raises Price Target to $9

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and raises the price target from $7 to $9.
Benzinga Newsdesk

Tue Apr 14, 2026

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Raises Price Target to $12

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target from $8 to $12.